Results 71 to 80 of about 22,030 (174)

Reactogenicity and immunogenicity of a new measles-mumps-rubella vaccine containing RIT 4385 mumps virus strain in healthy Turkish children

The Turkish Journal of Pediatrics, 2000
A total of 44 children aged between 15-18 months were randomly vaccinated either with a new measles-mumps-rubella (MMR) vaccine (Priorix, SmithKline Beecham) or a commercially available MMR vaccine (MMR-II, Merck) to compare the reactogenicity and
G Kanra, M Ceyhan, E Ozmert
doaj  

Risk factors for mumps in children under 15 years of age during the transition from single-dose to two-dose MMR vaccination strategy: a matched case-control study

Frontiers in Public Health
BackgroundThis study aimed to investigate the risk factors for mumps in children under 15 years of age during the transition from a single-dose to a two-dose measles–mumps–rubella (MMR) vaccine strategy, providing a scientific basis for public health ...
Huaxian Liu, Yan Xie, Zhongkui Zhu, Yuanbao Liu, Yang Yu, Jintao Wang, Lu Shen, Yunke Qian, Wanqin Tang   +8 more
doaj   +1 more source

Herd immunity to measles, rubella, and mumps in several Russian regions

Инфекция и иммунитет
Introduction. Mass vaccination, implemented in Russia within the framework of the Russia National Vaccination Calendar, is a key component in the fight against vaccine-preventable infections (measles, mumps, rubella). The aim.
Anna Yu. Popova, Vyacheslav S. Smirnov, Svetlana A. Egorova, Lidiya V. Buts, Angelika M. Milichkina, Valery A. Ivanov, Ekatherina M. Danilova, Oyuna B. Zhimbaeva, Victoria G. Drobyshevskaya, Oleg V. Kotsar, Olga P. Kurganova, Natalia A. Penkovskaya, Elena A. Babura, Natalya E. Potalitsina, Sergey V. Balakhonov, Natalya A. Sadykova, Natalya N. Zaytseva, Ekaterina N. Burdinskaya, Yulia A. Natykan, Svetlana A. Listopad, Liliya V. Mironova, Valentina I. Dubrovina, Anastasia V. Polyanina, Anna D. Kashnikova, Olga I. Deryabina, Margarita D. Senina, Nadezhda A. Likhanova, Nikolai G. Usovik, Natalya A. Berkovich, Zhanna R. Molchanova, Elena A. Kudryashova, Tatyana V. Arbuzova, Daria A. Starkova, Alena V. Svarval, Lyudmila V. Suzhaeva, Kristina A. Frolova, Areg A. Totolian   +36 more
doaj   +1 more source

Future perspectives of mumps vaccine

Uirusu, 2019
Because of the concerns about aseptic meningitis due to Japanese domestic mumps vaccine strains, the routine mumps immunization program has not yet been introduced in Japan, and it resulted in the situation where the major mumps epidemics occur every 4-5 years. However, the fact that at least 348 mumps hearing loss cases were reported during the recent
openaire   +3 more sources

Application Performance of Mumps Vaccine in Mumps

Transactions on Materials, Biotechnology and Life Sciences
Mumps a highly contagious disease, and it is caused by mumps virus. This research analyzed analyzes the research progress of mumps vaccine, and discussed the main problems faced by mumps vaccine. The live attenuated mumps vaccine has been used in most countries and regions for nearly 50 years since its introduction.
openaire   +1 more source

The effect of mumps vaccine on the incidence of mumps in Hefei: An interrupted time-series analysis. [PDF]

Hum Vaccin Immunother
Shi T, Qu G, Zhang Y, Hou L, Jin Y.
europepmc   +1 more source

Mumps Vaccine-Associated Aseptic Meningitis Complicated by Syndrome of Inappropriate Antidiuretic Hormone Secretion. [PDF]

Cureus
Yuki M, Kinoshita T, Yamada S, Tsuchida T, Hara Y.   +4 more
europepmc   +1 more source

Evaluation of Neonatal Sprague-Dawley Rats as a Potential Animal Model for the Neurovirulence Test of an Iranian Mumps Vaccine Strain, RS-12. [PDF]

Arch Razi Inst
Mohammad Kazem S, Mohammad T, Mohammad Hasan H, Ashraf M, Abolhasan F, Reza S, Mazyar S, Ali Reza Y.   +7 more
europepmc   +1 more source

Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial. [PDF]

Hum Vaccin Immunother
Habib MA, Hughes T, Huang LM, Deseda C, Zavadska D, Povey M, Raja R, Demoitié MA, Kondagunta VH, MMRVNS 20-001 study group.   +9 more
europepmc   +1 more source